CareDx Inc (CDNA) - Total Assets
Based on the latest financial reports, CareDx Inc (CDNA) holds total assets worth $532.99 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CareDx Inc - Total Assets Trend (2012–2025)
This chart illustrates how CareDx Inc's total assets have evolved over time, based on quarterly financial data. Also see CDNA market cap for the company's overall valuation and market capitalisation.
CareDx Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
CareDx Inc's total assets of $532.99 Million consist of 62.2% current assets and 37.8% non-current assets. Review CareDx Inc total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.8% |
| Accounts Receivable | $42.63 Million | 10.3% |
| Inventory | $26.70 Million | 6.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $31.96 Million | 7.7% |
| Goodwill | $40.34 Million | 9.8% |
Asset Composition Trend (2012–2025)
This chart illustrates how CareDx Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CareDx Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CareDx Inc's current assets represent 62.2% of total assets in 2025, a decrease from 77.0% in 2012.
- Cash Position: Cash and equivalents constituted 15.8% of total assets in 2025, down from 59.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 10.3% of total assets.
CareDx Inc Competitors by Total Assets
Key competitors of CareDx Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468
|
China | CN¥1.76 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
IZOTROPIC CORP.
F:1R3
|
Germany | €439.78K |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
CareDx Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.58 | 3.30 | 6.38 |
| Quick Ratio | 4.51 | 3.00 | 6.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $335.52 Million | $214.12 Million | $374.94 Million |
CareDx Inc - Advanced Valuation Insights
This section examines the relationship between CareDx Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.08 |
| Latest Market Cap to Assets Ratio | 6.26 |
| Asset Growth Rate (YoY) | -15.8% |
| Total Assets | $413.23 Million |
| Market Capitalization | $2.59 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values CareDx Inc's assets at a significant premium (6.26x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: CareDx Inc's assets decreased by 15.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CareDx Inc (2012–2025)
The table below shows the annual total assets of CareDx Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $413.23 Million | -15.85% |
| 2024-12-31 | $491.05 Million | +5.19% |
| 2023-12-31 | $466.83 Million | -14.03% |
| 2022-12-31 | $542.99 Million | -4.17% |
| 2021-12-31 | $566.62 Million | +53.76% |
| 2020-12-31 | $368.51 Million | +142.86% |
| 2019-12-31 | $151.74 Million | +16.10% |
| 2018-12-31 | $130.70 Million | +56.40% |
| 2017-12-31 | $83.56 Million | +8.91% |
| 2016-12-31 | $76.73 Million | +37.91% |
| 2015-12-31 | $55.64 Million | -9.00% |
| 2014-12-31 | $61.14 Million | +519.27% |
| 2013-12-31 | $9.87 Million | -0.03% |
| 2012-12-31 | $9.88 Million | -- |
About CareDx Inc
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart tr… Read more